| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $229.2M | +4.4% | +15.5% |
| R&D Expense | $18.0M | -1.3% | +3.3% |
| SG&A Expense | $58.8M | +0.5% | +9.1% |
| Operating Income | $52.6M | +23.6% | +49.9% |
| Pre-tax Income | $60.9M | +37.4% | +42.3% |
| Income Tax | $15.7M | +144.6% | +231.1% |
| Net Income | $28.3M |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $75.8M | -15.2% | +130.4% |
| Accounts Receivable | $1.6M | +54.7% | +155.2% |
| Current Assets | $589.0M | -9.9% | -1.1% |
| Total Assets | $1.13B | -4.6% | +31.1% |
| Current Liabilities | $632.7M | -15.6% | +13.4% |
| Total Liabilities |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | $174.0M | — | — |
| Capital Expenditures | $18.3M | — | — |
| Investing Cash Flow | $73.0M | — | — |
| Financing Cash Flow | -$238.9M | — | — |
| Free Cash Flow | $155.7M | — | — |
| +14.4% |
| +20.5% |
| $959.7M |
| -8.9% |
| +41.7% |
| Stockholders' Equity | $148.6M | +22.4% | +15.2% |